Skip to main content

Part of the book series: Developments in Cardiovascular Medicine ((DICM,volume 100))

  • 38 Accesses

Abstract

Study design must always depend on the objectives of the trial. In this paper, I will be talking about trials in phase II, III, and IV that are intended to determine whether a drug is safe and effective for use in altering lipids and lipoproteins for prevention of coronary artery disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Breier, C.H., Drexel, H., Lisch, H.J., Muhlberger, V., Herold, M., Knapp, E., Braunsteiner, H., Lancet 1985, 1:1242–1244

    Article  PubMed  CAS  Google Scholar 

  2. Boers, G.H.J., Smals, A.G.H., Trijbels, F.J.M., Fowler, B., Bakkeren, J.A.J.M., Schoonderwaldt, M.D., Kleijer, W.J., Kloppenborg, P.W.C., New Engl J Med 1985, 313:709–715

    Article  PubMed  CAS  Google Scholar 

  3. Barrett-Connor, E.,Khaw, K., Yen, S., New Engl J Med 1986, 315:1519–1524

    Article  PubMed  CAS  Google Scholar 

  4. Lipid Research Clinics Program, JAMA 1984, 251:351–364

    Article  Google Scholar 

  5. Canner, P.L., Berge, K.G., Wenger, N.K., Stamler, J., Friedman, L., Prineas, R.J., Friedewald, W., J Am Coll Cardiol 1986, 8:1245–1255

    Article  PubMed  CAS  Google Scholar 

  6. Committee of Principal Investigators, Br Heart J 1978, 40:1069–1118

    Article  Google Scholar 

  7. The Coronary Drug Project Research Group, JAMA 1970, 214:1303–1313

    Article  Google Scholar 

  8. The Coronary Drug Project Research Group, JAMA 1972, 220:996–1008

    Article  Google Scholar 

  9. The Coronary Drug Project Research Group, JAMA 1973, 226:652–657

    Article  Google Scholar 

  10. Multiple Risk Factor Intervention Trial ResearchGroup, JAMA 1982, 248:1465–1477

    Article  Google Scholar 

  11. University Group Diabetes Program, Diabetes 1970, 19:789–815

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 1989 Kluwer Academic Publishers

About this chapter

Cite this chapter

Troendle, G. (1989). What Levels of Cholesterol should be Studied and What Should be the Study Designs?. In: Morganroth, J., Moore, E.N. (eds) Risk/Benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic, and Hypolipidemic Agents. Developments in Cardiovascular Medicine, vol 100. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-1605-3_14

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-1605-3_14

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4612-8888-6

  • Online ISBN: 978-1-4613-1605-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics